Perfluorodichlorooctane | 135941-34-3

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代烷
• 英文名称: Perfluorodichlorooctane
• 英文别名: 1,1-dichloro-1,2,2,3,3,4,4,5,5,6,6,7,7,8,8,8-hexadecafluorooctane
• CAS: 135941-34-3
• 化学式: C₈Cl₂F₁₆
• 分子量: 470.96
• InChiKey: BOEIBTHDYSPVLT-UHFFFAOYSA-N

物化性质

• 沸点：
  175.8±35.0 °C(Predicted)
• 密度：
  1.738±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  7
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  16

文献信息

• MEDICINAL PREPARATION
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP1787661A1

  公开（公告）日：2007-05-23

  A pharmaceutical preparation has a ligand structure specifically recognizing a target site and an amphiphilic compound having a hydrophobic or amphiphilic group. The pharmaceutical preparation employs an amphiphilic compound of specific structure obtained by introducing a chained hydrophilic group with an appropriate flexibility, and thus becomes a fine particle suited for drug targeting. The pharmaceutical preparation is expected to give a prolonged pharmacological effect. A particulate preparation exhibiting a remarkable site targeting property can be formed. Further, according to the selection of matrix forming material, the drug releasing property can be controlled.

  一种药物制剂具有特异性识别靶位点的配体结构和具有疏水或两性亲和性基团的两性化合物。该药物制剂采用通过引入具有适当柔韧性的链状亲水基团获得的特定结构的两性化合物，因此成为适用于药物靶向的细颗粒。 预计该药物制剂将产生持久的药理效应。可以形成具有显著靶向性能的颗粒制剂。此外，根据基质形成材料的选择，可以控制药物释放性能。
• NANOEMULSIONS AND USE THEREOF AS CONTRAST AGENTS
  申请人：GUERBET

  公开号：US20140234223A1

  公开（公告）日：2014-08-21

  The invention relates to an oil-in-water nanoemulsion for MRI, including: an aqueous phase, a fluorinated phase including at least one fluorinated oil, a surfactant at the interface between the aqueous and fluorinated phases, the surfactant comprising: at least one amphiphilic targeting ligand, at least one amphiphilic lipid, and at least one diblock or triblock fluorophilic compound, as well as to the use thereof as a contrast agent.

  这项发明涉及一种用于磁共振成像的油包水纳米乳液，包括： 水相， 含有至少一种氟化油的氟化相， 位于水相和氟化相之间的表面活性剂，所述表面活性剂包括： 至少一种两性靶向配体， 至少一种两性脂质，以及 至少一种二嵌段或三嵌段亲氟化合物， 以及将其用作对比剂的用途。
• [EN] PHOTOSENSITIZER PARTICLES FOR MEDICAL IMAGING AND/OR PHOTODYNAMIC THERAPY<br/>[FR] PARTICULES DE PHOTOSENSIBILISATEUR DESTINÉES À L'IMAGERIE MÉDICALE ET/OU À LA THÉRAPIE PHOTODYNAMIQUE
  申请人：DCB USA LLC

  公开号：WO2014189796A1

  公开（公告）日：2014-11-27

  Photosensitizer particle contrast agents are suitable for medical imaging and/or photodynamic therapy. The photosensitizer particle contrast agent has a shell and a core encased by the shell. The shell consists essentially of multiple photosensitizer conjugates. Each photosensitizer conjugate consists of a photosensitizer and at least one biodegradable polymer covalently bound to the photosensitizer. The core has an echogenic contrast-enhancing material loaded therein. The photosensitizer of at least one of the multiple photosensitizer conjugates has a magnetic contrast-enhancing agent, e.g., a paramagnetic ion, chelated thereto. Methods for medical imaging use imaging compositions containing the photosensitizer particle contrast agents.

  光敏剂颗粒对比剂适用于医学成像和/或光动力疗法。光敏剂颗粒对比剂具有一个被壳包裹的壳和核心。壳主要由多个光敏剂结合物组成。每个光敏剂结合物由光敏剂和至少一个与光敏剂共价结合的可生物降解聚合物组成。核心中装载有增强超声对比的材料。多个光敏剂结合物中至少一个的光敏剂具有磁性增强对比剂，例如，螯合到其中的顺磁离子。用于医学成像的方法使用含有光敏剂颗粒对比剂的成像组合物。
• [EN] FLUOROPOLYMER EMULSIONS WITH PERHALOGENATED STABILIZER FOR THE DELIVERY OF HYDROPHOBIC DRUGS<br/>[FR] ÉMULSIONS DE FLUOROPOLYMÈRES AVEC STABILISATEUR PERHALOGÉNÉ POUR L'ADMINISTRATION DE MÉDICAMENTS HYDROPHOBES
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2015164756A1

  公开（公告）日：2015-10-29

  The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers and perhalogenated fluorous compounds, such as perfluorooctyl bromide or perfluorodecalin, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth (e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients. In certain embodiments, emulsion-based formulations are provided that are capable of supporting controlled release, for example, over a range of rates useful for clinical applications including rapid and sustained release.

  本发明提供治疗配方，包括治疗纳米乳剂，以及相关的方法，用于体内输送疏水性化合物，包括一类重要的疏水性麻醉剂。该发明的配方和方法包括半氟化块共聚物和全氟化氟化合物，例如全氟辛基溴化物或全氟癸烷，能够形成稳定的纳米乳剂，无需传统的支持细菌和/或真菌生长的脂质成分（例如大豆油和类似脂质）。在某些实施方式中，提供了基于乳剂的配方，能够制备、输送和释放对一系列临床应用有效的疏水药物，包括诱导和维持患者麻醉。在某些实施方式中，提供了基于乳剂的配方，能够支持受控释放，例如在一系列有用于临床应用的速率范围内，包括快速和持续释放。
• [EN] FLUOROPOLYMER EMULSIONS WITH BRANCHED SEMIFLUORINATED BLOCK COPOLYMER OR PHOSPHOLIPID SURFACTANT FOR THE DELIVERY OF HYDROPHOBIC DRUGS<br/>[FR] ÉMULSIONS DE FLUOROPOLYMÈRES COMPORTANT DES COPOLYMÈRES SÉQUENCÉS SEMI-FLUORÉS ET RAMIFIÉS OU UN TENSIOACTIF PHOSPHOLIPIDIQUE POUR L'ADMINISTRATION DE MÉDICAMENTS HYDROPHOBES
  申请人：WISCONSIN ALUMNI RES FOUND

  公开号：WO2015164781A1

  公开（公告）日：2015-10-29

  The present invention provides therapeutic formulations, including therapeutic nanoemulsions, and related methods for the in vivo delivery of hydrophobic compounds, including an important class of hydrophobic anesthetics. Formulations and methods of the invention include semifluorinated block copolymers, and optionally phospholipid surfactants, capable of forming a stable nanoemulsion without the need of conventional lipid components that support bacterial and/or fungal growth(e.g., soybean oil and similar lipids). In certain embodiments, emulsion-based formulations are provided that are capable of formulating, delivering and releasing amounts of hydrophobic drugs effective for a range of clinical applications, including inducing and maintaining anesthesia in patients. In certain embodiments, emulsion-based formulations are provided that are capable of supporting controlled release, for example, over a range of rates useful for clinical applications including rapid and sustained release.

  本发明提供了治疗配方，包括治疗纳米乳液，以及相关方法，用于体内传递疏水化合物，包括一类重要的疏水麻醉剂。本发明的配方和方法包括半氟化块共聚物，以及可选择的磷脂表面活性剂，能够形成稳定的纳米乳液，而无需传统的支持细菌和/或真菌生长的脂质成分（例如大豆油和类似脂质）。在某些实施例中，提供了基于乳液的配方，能够制备、传递和释放对一系列临床应用有效的疏水药物量，包括在患者中诱导和维持麻醉。在某些实施例中，提供了基于乳液的配方，能够支持受控释放，例如，在一系列对于临床应用有用的速率范围内，包括快速和持续释放。